In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3 by Costa, Maria do Carmo et al.
Costa Maria do Carmo (Orcid ID: 0000-0001-8466-4864) 
 
 
In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 
 
Maria do Carmo Costa, PhD,1* Maria Radzwion, BSc,1 Hayley S. McLoughlin, PhD,1 Naila S. 
Ashraf, MSc,1 Svetlana Fischer, MSc,1 Vikram G. Shakkottai, MD, PhD,1,2 Patrícia Maciel, PhD,3 
Henry L. Paulson, MD, PhD,1 Gülin Öz, PhD,4 
 
1Department of Neurology, University of Michigan, Ann Arbor, MI, USA; 2Departments of 
Molecular & Integrative Physiology and of Medicine, University of Michigan, Ann Arbor, MI; 3Life 
and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 
Portugal; 4Center for Magnetic Resonance Research, Department of Radiology, Medical School, 





Maria do Carmo Costa, Ph.D. 
Department of Neurology, University of Michigan 
A. Alfred Taubman Biomedical Sciences Research Building, Room 4027 
109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA 
Phone: +1 734-764-4094 
E-mail address: mariadoc@med.umich.edu  
 
This article is protected by copyright. All rights reserved.
This is the author manuscript accepted for publication and has undergone full peer review but
has not been through the copyediting, typesetting, pagination and proofreading process, which





Word count: 4846 words 
Running title: Neurochemical profiles of SCA3 transgenic mice 




Background: No treatment exists for the most common dominantly inherited ataxia Machado-
Joseph disease, or spinocerebellar ataxia type 3 (SCA3). Successful evaluation of candidate 
therapeutics will be facilitated by validated noninvasive biomarkers of disease pathology 
recapitulated by animal models.  
Objective: We sought to identify shared in vivo neurochemical signatures in two mouse models 
of SCA3 that reflect the human disease pathology. 
Methods: Cerebellar neurochemical concentrations in homozygous YACMJD84.2 (Q84/Q84) 
and hemizygous CMVMJD135 (Q135) mice were measured by in vivo magnetic resonance 
spectroscopy at 9.4 tesla. To validate the neurochemical biomarkers, levels of neurofilament 
medium (NFL, indicator of neuroaxonal integrity) and myelin basic protein (MBP, indicator of 
myelination) were measured in cerebellar lysates from a subset of mice and patients with SCA3. 
Finally, NFL and MBP levels were measured in cerebellar extracts of Q84/Q84 mice upon 
silencing of the mutant ATXN3 gene.  
Results: Both Q84/Q84 and Q135 mice displayed lower N-acetylaspartate than wild-type 
littermates, indicating neuroaxonal loss/dysfunction, and lower myo-inositol and total choline, 
indicating disturbances in phospholipid membrane metabolism and demyelination. Cerebellar 




NFL and MBP levels were accordingly lower in both models, as well as in the cerebellar cortex 
of patients with SCA3 than controls. Importantly, N-acetylaspartate and total choline correlated 
with NFL and MPB, respectively, in Q135 mice. Long-term sustained RNAi-mediated reduction 
of ATXN3 levels increased NFL and MBP in Q84/Q84 cerebella.  
Conclusions: N-acetylaspartate, myo-inositol and total choline levels in the cerebellum are 
candidate biomarkers of neuroaxonal and oligodendrocyte pathology in SCA3, aspects of 
pathology that are reversible by RNAi therapy. 
  






With increasing human lifespan, numerous age-related neurodegenerative diseases of diverse 
etiologies are becoming more prevalent. Nine such disorders are caused by an expanded CAG 
triplet repeat in genes that encode an abnormally longer polyglutamine (polyQ) tract in the 
respective disease proteins1, 2. Since the identification of these disease genes in the 1990s, 
increased understanding of the molecular basis of polyQ disorders led to several potentially 
efficacious therapies that were tested in animal models. Nucleotide-based reduction of CAG-
containing transcripts using nucleic acids has proven to be a particularly compelling therapeutic 
strategy for polyQ diseases in pre-clinical studies3-7, and clinical trials are underway for 
Huntington disease using antisense oligonucleotides (ASOs)8. Other gene and pharmacological 
therapeutic approaches for polyQ disorders are also in the pipeline9-11. Readiness for these 
upcoming clinical trials depends on the availability of disease biomarkers that allow noninvasive 
monitoring of aspects of cerebral disease pathology to assess therapeutic efficacy. 
Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is a polyQ 
disease caused by an expanded CAG repeat in the ATXN3 gene12 that leads to selective 
dysfunction and loss of neurons of specific nuclei in the cerebellum, brainstem, midbrain, spinal 
cord, and peripheral nerves9-11, 13-21. The disease manifests in patients with SCA3 as ataxia and 
a variable degree of other manifestations, including extrapyramidal signs, neuropathy, 
ophthalmoplegia, and muscle atrophy22-26. 
SCA3 is one of the polyQ diseases for which clinical trials are forthcoming. ASOs27-30, 
other RNA interference molecules31, 32, and pharmacological agents such as the selective 




serotonin reuptake inhibitor, citalopram33-35, showed preclinical efficacy to mitigate molecular, 
pathological, and phenotypic SCA3-like signs in transgenic mice.  
The success of upcoming human trials of these agents will be facilitated by the 
availability of validated noninvasive biomarkers of cerebral and cerebellar pathology. To this 
end, a number of studies have demonstrated an ability to detect macro- and micro-structural 
and neurochemical abnormalities noninvasively by magnetic resonance imaging14, 36-38 (MRI) 
and spectroscopy39-41 (MRS) in SCA3. While macrostructural disease-associated changes 
detectable by conventional MRI clearly mark tissue loss, other MR metrics may allow 
noninvasive monitoring of aspects of pathology that precede cell loss and atrophy, and hence 
may be reversible with treatments. However, such MR metrics need to be validated by 
comparing them to tissue pathology.  
Here, using MRS at 9.4 tesla (T), we sought to identify cerebellar neurochemical 
signatures in two mouse models of SCA3 that are extensively used in SCA3 preclinical trials: 
homozygous YACMJD84.2 (Q84/Q84)31, 42 and hemizygous CMVMJD135 (Q135)43 mice. We 
assessed two models to identify the common neurochemical abnormalities that may provide 
signatures of SCA3 pathology. To validate identified potential neurochemical biomarkers and 
determine which aspects of pathology they reflect, we evaluated cerebellar demyelination and 
neuroaxonal pathology in the same mice, as well as brain tissue from patients with SCA3. 
Finally, we determined whether RNAi-mediated silencing of the SCA3 gene reverses cerebellar 
demyelination and axonopathy in the Q84/Q84 model, since evidence of reversibility would 
suggest noninvasive myelin and neuronal markers could reflect therapeutic efficacy in future 
trials.        





Materials and Methods 
 
Experimental design 
The study was designed to assess MRS neurochemical profiles of two transgenic models 
frequently used in preclinical trials for SCA3– homozygous YACMJD84.2 (Q84/Q84)42 and 
hemizygous CMVMJD135 (Q135)43 mice. All animal procedures were approved by the 
University of Michigan Committee on the Use and Care of Animals (Protocol PRO00003836) 
and by the University of Minnesota Institutional Animal Care and Use Committee (Protocol 
1207A17510). Groups of Q84/Q84 (N=14 (7F/7M), 9-17 month-old) and their littermate non-
transgenic (wt) mice (N=11 (7F/4M), 11-18 month-old), and Q135 (N=9 (3F/6M), 8-16 month-
old) and their wt littermates (N=8 (5F/3M), 10-16 month-old) in the C57Bl6/J background 
(Supplementary Table 1) were scanned. Mice were housed in cages of maximum five animals 
and maintained in a standard 12-hours light/dark cycle with food and water ad libitum. 
Peripheral blood was collected by tail vein snip for a subgroup of Q84/Q84 mice (N=5) and 
littermate controls (N=4) to analyze liver profiles. Mice were shipped from the University of 
Michigan to the University of Minnesota for MR scanning, 2-4 weeks prior to scans. After MR 
scanning, mice were deeply anesthetized with sodium pentobarbital (100mg/kg i.p.), sacrificed 
by transcardial perfusion with pH 7.4 phosphate buffered saline and tissues were sent back to 
the University of Michigan for post-mortem analyses for demyelination (myelin basic protein 
(MBP), Luxol fast blue), axonopathy (neurofilament medium (NFL)), assessment of molecular 
layer thickness and Purkinje cell count.  




To investigate if the pathological features identified in SCA3 mice reflect the human condition 
we obtained deidentified frozen and fixed samples from the cerebellar cortex of autopsied brains 
from molecularly confirmed SCA3 (N=6) and control individuals (N=5) from the University of 
Michigan Brain Bank. (See Supplementary Table 2 for demographic information).   
To verify if RNAi-mediated depletion of human mutant ATXN3 rescues cerebellar molecular 
phenotypes in SCA3 mice, we used protein lysates from cerebella of end-stage Q84/Q84 mice 
(10-20 month old) that, at 6-8 weeks-of-age, were injected in the deep cerebellum nuclei with an 
adeno-associated virus (AAV2/1) encoding an artificial microRNA targeting mutant ATXN3 
(miRATXN3) (N=10) or with vehicle (N=10)31.  
 
Mouse genotyping and (CAG)n size assessment  
Genotyping was performed by PCR using DNA isolated from tail biopsy at weaning as 
previously described42, 43. (CAG)n size in Q84/Q84 and Q135 mice (Supplementary Table 1), 
and in SCA3 and control individuals (Supplementary Table 2) was determined at Laragen Inc. 
by gene fragment analysis.  
 
In vivo measurements 
Magnetic resonance (MR) protocol  
Procedures for anesthesia and MR scanning were identical to our prior studies44, 45. Mice were 
induced with 3-4% isoflurane and were maintained anesthetized with 1.5-2% isoflurane during 
scanning. Body temperature was maintained at 36-37ºC and respiration rate at ~70-100 breaths 
per minute. The scanning time for each animal was approximately 50 minutes. MR scans were 




performed using a quadrature surface RF coil and a 9.4 T/31 cm magnet (Magnex Scientific, 
Abingdon, UK) interfaced to an Agilent console (Agilent, Inc., Palo Alto, CA, USA). A cerebellar 
volume-of-interest (VOI, 5-7µl, placed based on anatomical landmarks to avoid inclusion of 
cerebrospinal fluid (CSF), Fig. 1A, 2A) was selected on coronal and sagittal multi-slice images 
obtained with a rapid acquisition with relaxation enhancement (RARE) sequence46. First- and 
second-order shims were adjusted using FASTMAP47. Localized 1H MR spectra were acquired 
with a localization by adiabatic selective refocusing (LASER) sequence (echo time TE=15ms, 
repetition time TR=5s, 256 averages)48, as described previously44, 45. Spectra were saved as 
single scans, which were frequency and phase corrected49. Frequency drifts were corrected in 
the time domain after peak picking in frequency domain (the tCr peak at 3ppm) by using the first 
transient as reference. Similarly, phase correction was done in the time domain by calculating 
the phase difference between the reference (first) transient and other transients. Transients that 
showed evidence for motion (substantial deviations in frequency, linewidth, signal-to-noise ratio 
(SNR), loss of water suppression efficiency relative to other transients) were excluded prior to 
averaging49. In the 23 spectra obtained from the Q84/Q84 cohort (mice that were included in the 
MRS analysis), 1-2 shots (out of 256) were excluded in 3 spectra, 45 shots were excluded in 
one spectrum and the acquisition had to be stopped due to gasping in one mouse, generating 
110 usable shots. The remaining 18 spectra had all 256 shots. In the 14 spectra obtained from 
the Q135 cohort (mice that were included in the MRS analysis), 5 shots were excluded in one 
spectrum and 93 shots were excluded in another spectrum. The remaining 12 spectra had all 
256 shots. Finally, the averaged spectra were corrected for eddy current effects using the 
unsuppressed water signal acquired from the same VOI50. 




Metabolite quantification  
Metabolites were quantified using LCModel51 relative to unsuppressed water spectra acquired 
from the same VOI, as described before44, 45. Reliable concentrations were selected based on 
Cramér-Rao lower bounds (CRLB) criteria (quantification with CRLB≤20% in the majority of the 
spectra).  Alanine, aspartate, glycine and scyllo-inositol were excluded from final analysis based 
on these criteria.  If the correlation between two metabolites was consistently high (correlation 
coefficient<-0.5), their sum was reported52. Strong negative correlation was found between 
creatine and phosphocreatine and between glycerophosphocholine + phosphocholine, therefore 
total creatine (tCr) and total choline (tCho) were reported.  Based on these reliability criteria,14 
concentrations were evaluated: ascorbate (Asc), γ-aminobutyric acid (GABA), glucose (Glc), 
glutamine (Gln), glutamate (Glu), glutathione (GSH), myo-inositol (myo-Ins), lactate (Lac), N-
acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), phosphoethanolamine (PE), taurine 
(Tau), tCr and tCho. 
Liver profile 
Peripheral blood collected from mouse tail vein snip was immediately centrifuged at maximum 
speed and serum was collected and stored at -80ºC. Serum samples were thawed, centrifuged 
and supernatants were loaded in VetScan® Mammalian Liver Profile reagent rotors (Abaxis, 
Inc.), which in turn were read in a VetScan Chemistry Analyzer providing quantitative 
determinations of albumin (ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
bile acids (BA), blood urea nitrogen (BUN), total cholesterol (CHOL), gamma glutamyl 
transferase (GGT).  
   






Extracts of soluble proteins in RIPA buffer from mouse cerebella or human cerebellar cortex 
were obtained using an established protocol31. Lysates from soluble protein fractions were 
resolved on 10% SDS-PAGE gels, and corresponding PVDF membranes were incubated 
overnight at 4ºC with primary antibodies: rat anti-MBP (1:1000; MCA409S, AbDSerotec), mouse 
anti-160kD NFL (1:1000; ab7794, Abcam), rabbit anti-α-tubulin (1:5000; 2144S, Cell Signaling), 
mouse anti-GAPDH (1:10000; MAB374, Millipore), and rabbit anti-MJD (1:20000). Bound 
primary antibodies were visualized by peroxidase-conjugated anti-rat, anti-mouse or anti-rabbit 
secondary antibodies (1:10000; Jackson Immuno Research Laboratories) followed by treatment 
with ECL-plus reagent (PerkinElmer) and exposure to autoradiography films. Band intensity was 
quantified by densitometry using ImageJ. 
Luxol fast blue staining  
Five-µm paraffin sections of cerebellar lobules from aged-matched patients with SCA3 and 
unaffected individuals were simultaneously deparaffinized in xylene and stained with Luxol fast 
blue. Briefly, sections were dewaxed in xylene, washed in absolute ethanol and 95% ethanol, 
stained overnight in 0.1% Luxol fast blue in acidic 95% ethanol, washed in 95% ethanol, 
differentiated in 0.05% lithium carbonate solution for 30 seconds, rinsed in distilled water and 
washed in 70% and 90% ethanol, washed in absolute ethanol, fixed in xylene and mounted in 
DPX mountant. Slides were imaged in a bright-field Olympus BX51 microscope.  
Immunofluorescence staining 




Left mouse brain hemispheres were fixed overnight in 4% paraformaldehyde, embedded in 30% 
sucrose/phosphate-buffered saline, and sectioned on a sledge microtome (SM200R; Leica 
Biosystems). Triple immunofluorescent labelling of free-floating 40-μm sagittal sections was 
conducted as previously31, using rat anti-MBP (1:50), mouse anti-NFL (1:500), rabbit anti-
ATXN3 (anti-MJD 1:2000), secondary mouse Alexa Fluor 488, rat Alexa Fluor 568 antibodies, 
and rabbit Alexa Fluor 647 (Invitrogen), and 4,6-diamidino-2-phenylindole dihydrochloride 
(DAPI). Sections were mounted with Prolong Gold Antifade Reagent (Invitrogen) and imaged in 
an Olympus IX71 microscope. Measurements of molecular layer thickness were made as 
previously described53. Briefly, using images from the triple immunostaining, two measurements 
were made at the depth of the primary fissure and two others at 100 µm from there. Purkinje 
neuron cell counts were obtained as the total number of neurons in the region of the primary 
fissure folium. 
Liver Hematoxylin & Eosin (H&E) histology 
Livers from four Q84/Q84 mice and one littermate control used in the MRS studies were fixed in 
10% formalin, paraffin embedded, and four-µm paraffin sections were stained with H&E and 
observed in a bright filed microscope.  
 
Statistical Analysis  
Characteristics of transgenic and control groups were compared using the two-tailed, unpaired 
Student’s t-test for age and spectral quality metrics (linewidth and SNR obtained from LCModel) 
and chi-square test for sex. Levels of neurochemicals and proteins were compared between the 
transgenic and control groups using Student’s t-test as all distributions were normal and showed 




homogeneous variances. Linear regression analyses were performed to evaluate the 
relationship between neurochemical concentrations and protein levels using Pearson 
correlation. A P<0.05 was considered statistically significant in all analyses. P-values were not 
corrected across the multiple metabolites due to the exploratory nature of our analysis and to 




Homozygous Q84/Q84 and hemizygous Q135 transgenic mice show shared 
neurochemical alterations in the cerebellum as measured by in vivo MRS 
Q84/Q84 and Q135 SCA3 transgenic mice show early onset of SCA3-like phenotypes starting 
around 6 weeks-of-age31, 43 and therefore are often used in preclinical trials31, 35, 43, 53-56. We 
investigated common neurochemical biomarkers in these two models that could serve as 
outcome measures in preclinical trials. 
Because no in vivo MRS studies were previously conducted in SCA3 mouse models, we 
obtained MR spectra at ultra-high field from the cerebellar vermis of symptomatic homozygous 
Q84/Q84, hemizygous Q135 and their littermate wt controls at an age when Purkinje cell 
dysfunction and pathology was previously shown in related transgenic mouse models35, 53. Two 
Q84/Q84 mice, two Q135 mice and one Q135 wt control were found to have an abnormal high 
Gln profile that was previously described in the brains of mice derived from the C57BL/6 strain57, 
58. The abnormal profile consisted of 2-3 fold higher Gln, 35-60% lower myo-Ins and 10-35% 
lower Tau relative to other wt or SCA3 mice in the same group. Because this profile results from 




portosystemic shunting in the liver57, which causes alterations in gene expression in many 
organs, these 5 mice were excluded from further analysis.  
SCA3 transgenic mice and their wt controls included in the MRS analyses were matched 
for age (Q84/Q84 13.4±2.1 (mean±SD) vs. wt 13.7±2.0 months, P=0.71; Q135 14.7±3.0 vs. wt 
15.1±2.3 months, P=0.77) and sex (Q84/Q84 7M/5F vs. wt 4M/7F, P=0.41; Q135 4M/3F vs. wt 
2M/5F, P=0.59). In addition, spectral quality was comparable in the SCA3 vs. wt groups 
(Linewidths Q84/Q84 10.0±2.2 (mean±SD) vs. wt 9.7±1.5 Hz, P=0.67; Q135 12.6±4.1 vs. wt 
10.3±1.5 Hz, P=0.19; SNR Q84/Q84 30.6±7.6 vs. wt 31.7±4.0, P=0.67; Q135 28.7±3.5 vs. wt 
27.4±3.2, P=0.49). Finally, structural images did not indicate substantial atrophy in SCA3 vs. wt 
mice (Figures 1A and 2A) and the VOI did not contain CSF. Therefore, group differences 
observed in the neurochemical profiles could not be due to group differences in age, sex, 
atrophy or spectral quality.    
Neurochemical profiles of Q84/Q84 mice (N=12), with predominant CAG repeat size 
ranging from 69 to 74 triplets (Supplementary Table 1), showed significantly higher Gln and 
lower levels of total NAA (tNAA), NAA, Glc, myo-Ins, Tau, and tCho compared to wt littermates 
(N=11) (Figure 1A,B). Because sex matching was imperfect between groups and the severity of 
the phenotype may be sex-dependent in SCA3 mice, we further investigated the neurochemical 
profiles of male and female mice only. We observed the same neurochemical trends in male 
and female mice analyzed separately, except for the myo-Ins difference that appeared to be 
primarily driven by female mice (Supplementary Figure 1). This was consistent with a lack of 
sex-differences of the motor phenotype in Q84/Q84 mice31. To investigate if the Gln levels in 
Q84/Q84 mice that were almost two times higher than their wt controls were due to liver 




dysfunction, we analyzed serum liver profiles and liver pathology in a subgroup of the mice 
included in the MRS analysis. These analyses revealed typical liver histology with no signs of 
portosystemic shunt in four Q84/Q84 mice (data not shown), and normal levels of liver analytes 
in mice of both genotypes (Supplementary Table 3) except in one wt mouse that showed bile 
acids >250 µmol/L, but normal liver H/E histology (data not shown), thereby excluding liver 
dysfunction as the cause of the detected high levels of Gln in Q84/Q84 transgenic mice.  
Cerebellar neurometabolite profiles of Q135 mice (N=7), with CAG repeat length ranging 
from 125 and 129 trinucleotides (Supplementary Table 1), revealed significantly lower levels of 
tNAA, NAA, Glu, myo-Ins, GSH, and tCho compared to controls (N=7) (Figure 2A,B). Similar to 
the Q84/Q84 mice, the same neurochemical trends were observed in male and female Q135 
mice analyzed separately (Supplementary Figure 2). Therefore, lower NAA and tNAA, tCho and 
myo-Ins represent the common neurochemical abnormalities in both SCA3 models 
(Supplementary Figure 3). In addition, groups of Q84/Q84 and Q135 mice were separated from 
wt controls with little or no overlap by plotting concentrations of these metabolites against each 
other (Figure 1C,2C).  
  
SCA3 transgenic mice show depletion of myelin basic protein (MBP) and neurofilament 
medium (NFL) in cerebellar extracts and slices and thinning of the molecular layer 
Because the three neurochemicals that allowed clear separation of both SCA3 transgenic 
mouse models from their respective controls suggest disturbances in the metabolism of 
membrane and myelin phospholipids59, 60 (myo-Ins and Cho) and neuroaxonal pathology61 




(NAA), and were all decreased in cerebella of SCA3 mice, we investigated whether these mice 
show cerebellar demyelination and axonal atrophy (Figure 3). 
Immunoblot analysis of cerebellar protein extracts from a subset (N=5 per group, 3F/2M) 
of the mice used to obtain neurochemical profiles (Figure 3A,D) revealed that the levels of MBP 
were indeed reduced to 31% of wt levels in Q84/Q84 mice (Figure 3B) and to 35% of wt levels 
in Q135 mice (Figure 3E). NFL abundance was also reduced to 13% of wt levels in cerebella of 
Q84/Q84 mice (Figure 3C) and to 11% of wt levels in Q135 mice (Figure 3F). Decreased 
cerebellar levels of MBP and NFL in Q84/Q84 and Q135 mice compared to controls were 
further evidenced by immunolabeling of these two proteins in cerebellar slices of these mice 
(N=4 animals per group) (Figure 3G). Triple immunofluorescence staining of MBP, NFL, and 
ATXN3 in cerebella of this subset of mice further revealed significantly thinner molecular layer in 
Q84/Q84 and Q135 mice than wt littermates (Supplementary Figure 4A), and a similar number 
of Purkinje cells in the primary fissure folia of mice from all genotypes (Supplementary Figure 
4B).    
 
In vivo myelin and neuronal markers measured by MRS correlate with post-mortem 
myelin and neuronal markers in SCA3 transgenic mice  
We next sought to determine if levels of tCho and/or myo-Ins are indicators of the status of 
myelination and if tNAA levels reflect axon integrity in the cerebellum. Hence, we investigated 
correlations between the levels of these neurochemicals with abundance of MBP and NFL 
proteins in the two SCA3 mouse models (Figure 3H,I, Supplementary Figure 5). Because of the 
small sample size per genotype group, correlation analyses were performed combining data 




from transgenic mice and corresponding wt littermates for each SCA3 transgenic mouse strain. 
Concentration of tCho correlated significantly with MBP levels (R2=0.928, P<0.001) (Figure 3H) 
and levels of tNAA correlated significantly with NFL expression in Q135 mice (R2=0.656, 
P=0.004) (Figure 3I). To test if the significance of tCho-MBP and tNAA-NFL correlations in 
Q135 mice was due to a genotype clustering effect we repeated the correlation analyses 
adjusting for the genotype. While both correlations remained significant adjusting for genotype 
(tCho-MBP, R2=0.929, P=0.000; tNAA-NFL, R2=0.658, P=0.023), we verified that MBP and tCho 
concentrations correlated independently of the genotype, and that NFL correlated with tNAA 
levels due to a combined effect of tNAA and genotype. No correlation was found between tCho 
and MBP levels, and tNAA and NFL concentrations in Q84/Q84 mice (Supplementary Figure 
5B,D), or between myo-Ins and MBP levels in either mouse model (Supplementary Figure 
5A,C).  
 
MBP and NFL are lower in the cerebellar cortex of patients with SCA3 than healthy 
controls 
To investigate whether dysregulation of cerebellar MBP and NFL in the two SCA3 transgenic 
mouse models reflects the human SCA3 condition, we assessed levels of these proteins in 
samples from cerebellar cortex of patients with SCA3 and healthy controls (Supplementary 
Table 2). Levels of MBP were decreased to 9% of control levels and NFL to 19% of control 
levels in cerebellar cortex of patients with SCA3 (Figure 4A-C) indicating demyelination and 
axonopathy in this brain region. Luxol fast blue staining of brains from patients with SCA3 and 




aged-matched unaffected individuals confirmed extensive demyelination in cerebella of patients 
with SCA3 that is more evident in aged patients (Figure 4D).   
 
Long-term sustained reduction of mutant ATXN3 rescues cerebellar myelination and 
neurofilament biomarkers in homozygous Q84/Q84 mice 
Because approaches to reduce levels of ATXN3 gene products are currently a promising 
candidate therapy for SCA3, we sought to evaluate whether long-term sustained RNAi-mediated 
decrease of mutant human ATXN3 (hATXN3) abundance in Q84/Q84 cerebella would prevent 
reduction of MBP and NFL. Therefore, we used cerebellar protein extracts from end-stage 
Q84/Q84 mice that were injected at 6-8 weeks-of-age in the DCN with an AAV encoding an 
artificial microRNA targeting mutant ATXN3 (miRATXN3)31. We previously showed that 
miRATXN3 reduced hATXN3 levels to ~40% of vehicle-injected Q84/Q84 mice31. Cerebella of 
miRATXN3-treated Q84/Q84 mice in fact showed MBP and NFL levels of, respectively, 137% 
and 177% than their levels in vehicle-treated Q84/Q84 mice (Figure 5A,B). Whereas no 
association was detected between MBP and hATXN3 levels (P=0.218) (Figure 5C), NFL levels 
were significantly correlated with levels of mutant hATXN3, demonstrating an association 
between the level of gene silencing and the extent of rescue of neuroaxonal pathology in 








Future human clinical trials that seek to successfully translate preclinical animal studies would 
be facilitated by validated imaging biomarkers of cerebellar pathology. Here we identified shared 
neurochemical abnormalities in the homozygous Q84/Q8431, 42 and hemizygous Q13543 
transgenic mice. Both of these models are well characterized models, reproduce several 
aspects of SCA3, and are extensively used in preclinical trials. We have further demonstrated 
associations of these noninvasive MR markers with protein markers of neuroaxonal pathology 
and demyelination, as well as the reversibility of these pathologies with mutant ATXN3 gene 
silencing.  
Previously cerebral and cerebellar metabolic alterations were only reported in one study 
that used in vitro 1H-MRS in brain tissue obtained from hemizygous Q84 mice62. The cerebellar 
neurometabolite spectra of homozygous Q84/Q84 mice showed similarities to the ones 
previously described in the in vitro study, namely higher Gln and lower NAA, tCho and myo-Ins 
in Q84/Q84 mice than wt controls62. Furthermore, the lower levels of tNAA observed in both 
models, lower levels of Glu in Q135 and higher levels of Gln in Q84/Q84 mice compared with 
controls, recapitulate prior observations in patients with SCA339, 41. Decrease of tNAA in the 
cerebellum is a common biomarker of neuronal dysfunction or loss displayed by patients 
affected with several SCAs (SCA1, SCA2, SCA3/MJD, SCA6, and SCA7)39, 41, 63, 64, SCA1 
mouse models44, 45, 65, and hemizygous Q84 mice62. The decreased Glu levels detected 
suggests dysfunction of glutamatergic granule cells, unipolar brush cells (UBCs), and/or parallel 
and climbing fibers in the cerebellar cortex66. While the number or function of these 
glutamatergic cells has not been investigated in cerebellar lobules of Q135 or Q84/Q84 mice, 
Purkinje cells (PCs) show decreased calbindin staining in Q135 mice35 and electrophysiological 




alterations in Q84 mice53 indicating that these cells are somehow dysfunctional. Because PCs 
receive excitatory input from parallel and/or climbing fibers, it is possible that Q135 PCs are 
impaired due to decreased input from these fibers into the molecular layer. End-stage Q84/Q84 
cerebella did not show decreased levels of Glu, but displayed increased concentration of Gln, 
which could suggest abnormal Glu-Gln cycle between glutamate cells and Bergmann glia in the 
molecular layer, and/or a higher number of glial cells that produce the bulk of Gln in the brain. 
While cerebellar cell loss in aged SCA3 mice needs to be further investigated, thinning of the 
molecular layer accompanied by preserved Purkinje cell number in these mice suggests that 
dysregulated levels of tNAA, Glu and Gln reflect neuronal dysfunction and dendritic atrophy 
rather than cell loss in these models, similar to prior observations in SCA1 models44.  
In addition to the above described neurochemical changes in SCA3 mice, each of the 
transgenic mouse groups showed a clear separation from their respective wild type controls in 
concentrations of tNAA, myo-Ins and tCho in the cerebellum (Figures 1C, 2C, Supplementary 
Figure 3). NAA is a validated marker of neuronal viability61 and a source of acetate for myelin 
lipid synthesis in oligodendrocytes67, myo-Ins is a structural sugar of membrane and myelin 
phospholipids39, and changes in tCho levels reflect disturbances in phospholipid metabolism67. 
Because all three metabolites were decreased in spectra of both SCA3 mouse models, we 
hypothesized that these mice would display cerebellar demyelination and axon atrophy. 
Demyelination, white matter and axon dysfunction and axonopathy have indeed been reported 
histopathologically in brain tissue obtained from patients with SCA317, 40, 41, and primary 
oligodendrocyte/myelin dysfunction indicated by diffusion MRI in SCA314. Furthermore, altered 
function of oligodendrocytes was recently reported in SCA3 models including the Q8468. Here, 




by showing that aged Q84/Q84 and Q135 cerebella and post-mortem cerebellar cortex from 
patients with SCA3 display reduced levels of MBP and NFL compared to their respective 
controls, we confirmed demyelination and axon loss in SCA3 cerebella. The magnitude of 
reduction that we detected in NFL in SCA3 cerebella relative to controls was markedly higher 
than the reduction in the in vivo neuronal marker, tNAA. Similarly, the magnitude of reduction in 
MBP in SCA3 was substantially higher than the % reduction in the MRS markers myo-Ins and 
tCho. This is likely because these neurochemicals have multiple roles, such as serving as 
metabolic intermediates and osmolytes, and therefore are less specific for neuroaxonal and 
myelin pathology than the post-mortem protein markers. However, importantly, the associations 
between tCho with MBP levels and tNAA with NFL abundance in the Q135 mice suggest that 
tCho and tNAA levels reflect the status of myelination and axon integrity in the cerebellum of 
these mice. This evidence supports the inclusion of MRS evaluation of these neurochemicals in 
preclinical trials using Q84/Q84 and Q135 mice to evaluate the efficacy of therapeutic agents in 
rescuing SCA3 pathology. 
While MBP levels were higher in miRATXN3-treated Q84/Q84 cerebella than wt 
controls, concentrations of MBP and hATXN3 did not correlate, possibly indicating that AAV2/1 
miRATXN3 poorly transduced oligodendrocytes, as expected for this virus serotype69.  
Cerebellar axon loss seems to be, however, a consequence of expression of toxic expanded 
ATXN3 since reduction of NFL concentration in Q84/Q84 cerebella was suppressed by long-
term decrease of mutant ATXN3 levels in miRATXN3-treated Q84/Q84 mice. NFL levels 
significantly correlated with hATXN3 abundance in the cerebella of Q84/Q84 mice suggesting 
that AAV2/1 miRATXN3 effectively transduced and reduced hATXN3 in the majority of 




cerebellar neurons. Importantly, the reversal of the neuroaxonal pathology with RNAi-mediated 
reduction of ATXN3 levels supports the use of noninvasive imaging markers of this pathology in 
future pre-clinical and clinical trials that evaluate similar gene silencing strategies. No MRS 
measurements are available for this set of RNAi-treated SCA3 mice31. Whether gene silencing 
will rescue the abnormal levels of the myelin and neuronal markers measured by MRS, similar 
to prior observations in SCA1 mice70, remains to be determined in future studies.     
The ultra-high field strength MRI scanner we used in this study is not widely available for 
human trials that will like utilize the widely available 3T platform. We previously demonstrated 
the feasibility of detecting neurochemical alterations in patients with SCAs at field strengths 
ranging from 3-7T39, 41, 63, 64, 71. Specifically, neurochemical abnormalities were reliably detected 
in SCA3 at 3T39. Thus, the current observations in SCA3 models can be obtained with 3T 
technology when similar optimized methods are used for MRS data acquisition and analysis. 
We have further shown good test-retest reproducibility of cerebellar neurochemical 
concentrations at 3T72 and the two-site reproducibility of cerebellar and brainstem 
neurochemical concentrations at 3T73. Finally, these MRS methods are now being validated for 
clinical trial readiness in SCA3 in an international, multi-site setting (https://readisca.org/).  
In summary, we have identified novel neurochemical and molecular similarities between 
end-stage homozygous Q84/Q84, aged hemizygous Q135 mice, and patients with SCA3, 
further supporting the use of these mouse models in preclinical trials of SCA3. Like patients with 
SCA3, both transgenic models show neurochemical signatures indicative of neuronal 
dysfunction, dysregulation of glutamatergic systems, and myelin and neurite loss. We also 
provide molecular confirmation of cerebellar myelin and axon damage in SCA3 mice and 




patients and establish significant associations of select neurochemical markers with invasive 
measures of myelin and axon damage. It will be important to perform future longitudinal MRS, 
molecular and pathological studies in parallel to evaluate the progression of neurometabolite 
dysregulation and associated molecular and pathological outcomes in the cerebellum and other 
SCA3-affected brain areas of transgenic mice. These novel neurochemical alterations in SCA3 
transgenic mice reflect important aspects of pathology and should enable noninvasive 
monitoring of pathology reversal in future preclinical trials of therapeutic agents for SCA3.  
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Figure 1: Cerebellar neurochemical levels are altered in homozygous Q84/Q84 mice. A) 
Representative localized proton MR spectra and midsagittal T2-weighted images of a Q84/Q84 
and a wt littermate mouse. The most prominent neurochemical abnormalities, namely lower 
tCho and higher Gln in Q84/Q84 compared to wt mice, are denoted in the spectra by arrows. B) 
Cerebellar neurochemical profiles of Q84/Q84 mice (N=12, black bars) and wt littermates 
(N=11, white bars). Bars represent average neurochemical concentration ± SEM. Comparison 
between mouse genotypes was performed using Student’s t-test and statistical significance is 
indicated as: ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001. C) Separation of Q84/Q84 mice (black 
squares) from controls (white squares) by plotting two altered metabolites against each other.  
 
Figure 2: Cerebellar neurochemical levels are altered in hemizygous Q135 mice. A) 
Representative localized proton MR spectra and midsagittal T2-weighted images of a Q135 and 
a wt littermate mouse. The most prominent neurochemical abnormalities, namely lower tCho 
and tNAA in Q135 compared to wt mice, are denoted in the spectra by arrows. B) Cerebellar 
neurochemical profiles of Q135 mice (N=7, grey bars) and wt littermates (N=7, white bars). Bars 
represent average chemical concentration ± SEM. Comparison between mouse genotypes was 
performed using Student’s t-test and statistical significance is indicated as: ∗P<0.05, ∗∗P<0.01, 
and ∗∗∗P<0.001. C) Separation of Q135 mice (grey squares) from controls (white squares) by 
plotting two altered metabolites against each other.  
 
Figure 3: Cerebella of SCA3 transgenic mice show decreased levels of myelin basic 
protein (MBP) and neurofilament medium (NFL) that correlate with concentrations of 




tCho and tNAA, respectively, in Q135 mice. A,D) Anti-ATXN3 immunoblot (anti-MJD 
antibody) detecting mutant human ATXN3 and endogenous mouse Atxn3 in cerebellar soluble 
protein extracts of the subset of Q84/Q84 (A), Q135 (D) and corresponding littermate wild type 
mice used to assess levels of MBP (B,E) and NFL medium (NFL) (C,F). Western blots show 
decreased levels of MBP and NFL in cerebella of Q84/Q84 (B,C) and Q135 (E,F) compared 
with controls. Graphs show quantification of protein bands by densitometry. Bars represent the 
average percentage of protein relative to respective wild type controls, normalized for α-Tubulin 
(± SEM). Statistical significance determined by Student’s t-test is indicated as ∗P<0.05. G) 
Representative images of immunofluorescent labelling of MBP (red) and NFL (green) show 
decreased signal of these two proteins in cerebella of Q84/Q84 and Q135 mice compared with 
corresponding litter mates (N=4 mice per group). Nuclei were labeled with DAPI (blue). Scale 
bar, 100 µm. H, I) Plots showing Pearson correlations of levels of MBP with tCho (H), and NFL 
with tNAA (I) in Q135 (grey circles), and their respective wt littermate mice (white circles). 
 
Figure 4: Cerebellar lobules of patients with SCA3 show decreased levels of MBP and 
NFL medium and demyelination. A) Anti-ATXN3 immunoblot (anti-MJD antibody) detecting 
expanded and normal ATXN3 in soluble protein extracts from cerebellar cortex of patients with 
SCA3 and control individuals. Detection of MBP (B) and NFL medium (C) by Western blotting 
shows lower levels of both proteins in patients compared with controls. Graphs show 
quantification of protein bands by densitometry. Bars represent the average percentage of 
protein relative to respective wild type controls, normalized for α-Tubulin (± SEM). Statistical 
significance determined by Student’s t-test is indicated as ∗P<0.05. D) Luxol fast blue staining 




of cerebellar sections shows signs of demyelination in patients with SCA3 compared with aged-
matched unaffected individuals, which is more evident in older patients. Scale bar, 200 µm. 
 
Figure 5: Cerebella from miRATXN3-treated Q84/Q84 show higher levels of MBP and NFL 
medium compared to vehicle-treated Q84 animals. Immunoblotting to detect MBP (A) and 
NFL (B) in cerebellar soluble protein extracts from end-stage Q84/Q84 mice injected with an 
adeno-associated virus delivering an artificial microRNA targeting ATXN3 transcripts 
(miRATXN3) or injected with vehicle. Graphs show quantification of protein bands by 
densitometry. Bars represent the average percentage of protein relative to levels in vehicle-
injected Q84/Q84 mice, normalized for α-Tubulin (± SEM). Black and blue bars indicate, 
respectively, vehicle-injected and miRATXN3-injected Q84/Q84 mice. Statistical significance 
determined by Student’s t-test is indicated as ∗∗P<0.01. Plots showing Pearson correlations of 
levels of MBP with hATXN3 (C) and of NFL with hATXN3 (D) in vehicle (black circles) or 
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readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines. 
Do not send in hard copies of these forms. 
[ ] Contributor-owned work 
Contributor’s signature Date 
Type or print name and title 
Co-Contributor’s signature Date 
Type or print name and title 
X 05/04/2020
Hayley S. McLoughlin, PhD
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[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
X
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Financial Disclosure 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Address:   
Type of support:   
This material will be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:    
Address:   
Type of support:   
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
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Hayley S. McLoughlin
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COPYRIGHT TRANSFER AGREEMENT 
Date:   
Contributor name:      
Contributor address: 
Manuscript number:   
Re: Manuscript entitled:    (the “Contribution”) 
for publication in:  Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period.   Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for
research funded by ESRC or AHRC. 
5. Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period.    Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable.
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
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D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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I. ACKNOWLEDGEMENTS
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines. 
Do not send in hard copies of these forms. 
[ ] Contributor-owned work 
Contributor’s signature Date 
Type or print name and title 
Co-Contributor’s signature Date 
Type or print name and title 
Henry L. Paulson 5/4/2020X
Henry L. Paulson MD PhD
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[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
X
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Exhibit A  
Financial Disclosure 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Address:   
Type of support:   
This material will be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:    
Address:   
Type of support:   
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
ATTACH ADDITIONAL INFORMATION AS NECESSARY  
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COPYRIGHT TRANSFER AGREEMENT 
Date: 
Contributor name:  
Contributor address: 
Manuscript number:   
Re: Manuscript entitled:    (the “Contribution”) 
for publication in:  Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period.   Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for
research funded by ESRC or AHRC. 
5. Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period.    Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable.
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
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D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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I. ACKNOWLEDGEMENTS
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines. 
Do not send in hard copies of these forms. 
[ ] Contributor-owned work 
Contributor’s signature Date 
Type or print name and title 
Co-Contributor’s signature Date 
Type or print name and title 
x 5/4/2020
Gulin Oz, Professor
           Gulin Oz
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[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
x
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Exhibit A  
Financial Disclosure 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Address:   
Type of support:   
This material will be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:    
Address:   
Type of support:   
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
ATTACH ADDITIONAL INFORMATION AS NECESSARY  
NIH
grant 
NIH, National Ataxia Foundation, Biogen, Inc.
grant
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COPYRIGHT TRANSFER AGREEMENT 
Date:   
Contributor name:      
Contributor address: 
Manuscript number:   
Re: Manuscript entitled:    (the “Contribution”) 
for publication in:  Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period.   Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for
research funded by ESRC or AHRC. 
5. Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period.    Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable.
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
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D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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I. ACKNOWLEDGEMENTS
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines. 
Do not send in hard copies of these forms. 
[ ] Contributor-owned work 
Contributor’s signature Date 
Type or print name and title 
Co-Contributor’s signature Date 
Type or print name and title 
05/04/2020
Maria do Carmo Costa, PhD
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[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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Exhibit A 
Financial Disclosure 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Address:   
Type of support:   
This material will be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:   
Address: 
Type of support: 
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
ATTACH ADDITIONAL INFORMATION AS NECESSARY  
Co-Investigator with effort in NIH grants; NAF grant; Sponsored Research Agreements with Alnylam Pharmaceuticals and with Exicure Inc.  
NINDS/NIH; National Ataxia Foundation (NAF); Alnylam Pharmaceuticals; Exicure Inc. 
Becky Babcox Research Fund, University of Michigan
Pilot research grant
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period.   Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for
research funded by ESRC or AHRC. 
5. Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period.    Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable.
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
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D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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Exhibit A  
Financial Disclosure 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Address:   
Type of support:   
This material will be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:    
Address:   
Type of support:   
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
ATTACH ADDITIONAL INFORMATION AS NECESSARY  
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COPYRIGHT TRANSFER AGREEMENT 
Date:   
Contributor name:      
Contributor address: 
Manuscript number:   
Re: Manuscript entitled:    (the “Contribution”) 
for publication in:  Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
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2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
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“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
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